Pfizer's once-daily Lyrica met goal of trial in fibromyalgia
(Reuters) - Pfizer Inc said on Monday a late-stage trial of a once-daily version of its drug Lyrica in patients with fibromyalgia, a pain condition affecting more than 5 million Americans, met its main goal.
Patients taking once-daily Lyrica, also known as pregabalin, went for a significantly longer period of time before feeling pain compared with patients who took a placebo.
The study is the second of three late-stage trials testing a controlled-release version of the drug, which is currently given several times a day.
A trial of the controlled-release version of the drug in patients with certain types of seizures did not meet its main goal, Pfizer said.
The company is also studying the drug in patients with neuralgia.
(Reporting By Toni Clarke; editing by John Wallace)
- Tesla prevails in top Massachusetts court over direct sales
- U.S. to Assad: Beware of interfering with U.S. air power in Syria
- Odile batters Mexico's Baja resorts, knocks out power to most area
- Iran supreme leader spurns U.S. overture to fight Islamic State |
- Quake strikes northeast of Tokyo, no reports of serious damage